Navigation Links
Old Drug Holds Promise Against Opportunistic Lung Bug
Date:8/19/2010

everyone at some point; the authors say that more than 80 percent of children have been infected by the age of 2. Most people shake off the infection without consequence, but for people with cancer, AIDS, or other diseases that compromise their immune system, the infection can be deadly. Usually there are few signs that the patient is sick until the infection is well established and the fungus is widespread in the lungs. Among cancer patients, mortality rates as high as 40 percent have been reported.

Since the body's immune response is central to how Pneumocystis kills patients, doctors use two different types of drugs in tandem to treat patients – an antibiotic to kill the bug, and steroids or another type of drug to reduce the consequent inflammation.

Central to the study were mice in which the disease progresses in a manner very similar to AIDS patients. The remarkable strides in AIDS therapy in recent years have come with a down side for many patients, thanks to Pneumocystis: When anti-retroviral therapy kicks in, a patient's immune system often becomes stronger very quickly – and if the fungus is present, the immune system attacks it vigorously, causing a potentially deadly form of pneumonia.

Wright's team looked at the effects in mice of sulfasalazine, an anti-inflammatory drug that has proven useful in treating conditions like Crohn's disease and rheumatoid arthritis. The team found that Pneumocystis-infected mice treated with sulfasalazine developed much less severe disease than untreated mice. The sulfasalazine-treated mice had better lung function, less weight loss, and were generally healthier than untreated animals.

While some of the benefit was due to the drug's anti-inflammatory properties and was expected, the result included a big surprise: The drug also spurs the body to remove the bug more aggressively by boosting the activity of immune cells called macrophages.

"This was unexpecte
'/>"/>

SOURCE University of Rochester Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sinovac Holds 2010 Annual Meeting of Shareholders
2. Roche Holds Seventh Annual Childrens Walk
3. European Patent Office Upholds Molecular Devices Planar Patch Clamp Patent
4. joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery
5. Calcitech Holds Annual General Meeting
6. New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
7. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
8. New Treatment for Autism Holds Promise
9. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
10. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
11. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... MANCHESTER, England , July 22, 2014 ... AEX:PHIA) announced today that The Christie NHS Foundation Trust ... center, will join a consortium whose mission is to ... imaging (MRI) guided radiation therapy system. Such a system ... real-time visualization of cancer targets. "The ...
(Date:7/22/2014)... 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and dosing of patients in its ongoing Phase 2 ... cancer under the revised clinical protocol agreed to with ... form of Halozyme,s proprietary recombinant human hyaluronidase under development ... "Our diligent effort to rapidly re-initiate ...
(Date:7/22/2014)... Fla. , July 22, 2014  Neurotrope Bioscience, ... signed a world-wide, exclusive license agreement with the Icahn ... ( Mount Sinai ) to utilize ... of Bryostatin-1 in the treatment of Niemann-Pick Type C ... are afflicted with Alzheimer-like symptoms. The license also covers ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... OKLAHOMA CITY, Jan. 6, 2011 Altheus Therapeutics, Inc., ... active-controlled Phase I clinical trial of the safety and ... left-sided, or distal, ulcerative colitis.  No serious adverse events ... excited to have achieved this milestone, as it prepares ...
... Calif., Jan. 6, 2011 Viveve, Inc. , ... it has received the European CE (Conformite Europeenne) mark ... non-surgical treatment of laxity of the vaginal introitus (opening), ... (Logo:   http://photos.prnewswire.com/prnh/20110106/SF25673LOGO ) "The CE mark ...
Cached Medicine Technology:Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis 2Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2
(Date:7/22/2014)... July 22, 2014 Dr. Jeremy K. ... surgical colleagues, have recently discussed the reasons for an ... in the periodontics profession are seeing the amount of ... exponentially. In fact, one surgeon reported that over 50% ... Although dental implants have a very high success rate ...
(Date:7/22/2014)... 2014 A Florida woman has filed ... alleges the death of her husband was the result ... Bernstein Liebhard LLP reports. According to her complaint, which ... the Southern District of Florida on June 23rd, the ... a subdural hemorrhage the following June. Despite emergency treatment, ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Michael DeBaun, MD, ... P. Hebbel, MD, of the University of Minnesota Medical ... for their significant research advances in the area of ... for the late Ernest Beutler, MD, a past president ... is a two-part lectureship that recognizes major translational advances ...
(Date:7/22/2014)... says women are often in the dark. Historically, it was ... has shown that post-menopausal women are just as likely as ... be adequately diagnosed and treated. New research from Western University ... Clinical Pharmacology brings to light a genetic basis for ... are more prone to heart disease. , The study, led ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
Breaking Medicine News(10 mins):Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:Gene variant identified as a heart disease risk factor for women 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3
... payment models that reward workers for meeting certain performance ... P4P programs use a variety of methods to reward ... bonuses. A new study in the ... appear to be effective in incentivizing low performing physicians. ...
... Government of ... the NGO Tostan to end the practice by 2015 , ... Dakar, Senegal (PRWEB) February 19, 2010 -- Building on a ... of communities in Senegal join its ranks in recent years, the Government of Senegal will ...
... , ... ... , , , ... ...
... ... recently launched a robust health encyclopedia offering health news and feature articles on vitamins, ... , ... (PRWEB) February 19, 2010 -- eVitamins™, a leading online retailer of vitamins, supplements and ...
... teaching health benefits, study finds , FRIDAY, Feb. 19 ... to exercise is to focus on the fun of ... "Our study shows that for inactive teenagers, emphasizing the ... way to encourage exercise than highlighting traditional health benefits," ...
... ... ... ... ...
Cached Medicine News:Health News:Senegal: Total End of Female Genital Cutting Now in Sight 2Health News:Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns 2Health News:Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns 3Health News:eVitamins Launches New Health Encyclopedia 2Health News:Teens Might Exercise More If They Think It's Fun 2Health News:MDS Announces Substantial Issuer Bid 2Health News:MDS Announces Substantial Issuer Bid 3Health News:MDS Announces Substantial Issuer Bid 4Health News:MDS Announces Substantial Issuer Bid 5Health News:MDS Announces Substantial Issuer Bid 6
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: